N-(3-Amino-propyl)-N-methyl-acetamide | 84598-51-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(3-Amino-propyl)-N-methyl-acetamide
• 英文别名: N-(3-aminopropyl)-N-methylacetamide
• CAS: 84598-51-6
• 化学式: C₆H₁₄N₂O
• mdl: MFCD11129667
• 分子量: 130.19
• InChiKey: PEMHCPZCFJGAEL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(3-Amino-propyl)-N-methyl-acetamide 以 乙腈 为溶剂， 反应 6.5h， 生成 tetrahydro-6-(N-methylacetamido)methyl-1H-azepine-2,5-dione
  参考文献：
  名称：

  Takechi, Haruko; Tateuchi, Sumiko; Machida, Minoru, Chemical and pharmaceutical bulletin, 1986, vol. 34, # 8, p. 3142 - 3152

  摘要：

  DOI：
• 作为产物：
  描述：

  N-[3-(benzylideneamino)propyl]-N-methylacetamide 在 盐酸 、 三乙胺 作用下， 生成 N-(3-Amino-propyl)-N-methyl-acetamide
  参考文献：
  名称：

  Takechi, Haruko; Tateuchi, Sumiko; Machida, Minoru, Chemical and pharmaceutical bulletin, 1986, vol. 34, # 8, p. 3142 - 3152

  摘要：

  DOI：

文献信息

• Novel carbapenem derivatives of quarternary salt type
  申请人：——

  公开号：US20030022881A1

  公开（公告）日：2003-01-30

  An objective of the present invention is to provide carbapenem derivatives which have potent antibiotic activity against MRSA, PRSP, Influenzavirus, and &bgr;-lactamase-producing bacteria and are stable against DHP-1. The compounds according to the present invention are compounds represented by formula (I) or pharmaceutically acceptable salts thereof: 1 wherein R 1 represents H or methyl; R 2 and R 3 each independently represent H, halogen, lower alkyl or the like; R 4 represents optionally substituted lower alkylthio or the like; and R 5 represents optionally substituted lower alkyl or the like.

  本发明的目的在于提供对MRSA、PRSP、流感病毒和β-内酰胺酶产生菌具有强大抗生素活性的碳青霉烯衍生物，且对DHP-1稳定。根据本发明的化合物是由公式(I)表示的化合物或其药物可接受的盐：1其中R1代表H或甲基；R2和R3各自独立地代表H、卤素、低级烷基等；R4代表可选地取代的低级烷基亚磺酰基等；R5代表可选地取代的低级烷基等。
• FUSED RING HETEROCYCLE KINASE MODULATORS
  申请人：Chen Chixu

  公开号：US20080261921A1

  公开（公告）日：2008-10-23

  The present invention provides fused ring heterocycles as kinase modulators, pharmaceutical compositions containing these modulators, and methods of using these modulators to treat diseases mediated by kinase activity.

  本发明提供了融合环杂环化合物作为激酶调节剂，含有这些调节剂的药物组合物，以及使用这些调节剂治疗由激酶活性介导的疾病的方法。
• [EN] LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS<br/>[FR] LIPIDES DESTINÉS À ÊTRE UTILISÉS DANS DES FORMULATIONS DE NANOPARTICULES LIPIDIQUES
  申请人：ACUITAS THERAPEUTICS INC

  公开号：WO2019036000A1

  公开（公告）日：2019-02-21

  Compounds are provided having the following structure (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8, L1, L2, G1, G2, G3, a, b, c and d are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

  提供具有以下结构（I）或其药学上可接受的盐、互变异构体或立体异构体的化合物，其中R1a、R1b、R2a、R2b、R3a、R3b、R4a、R4b、R5、R6、R7、R8、L1、L2、G1、G2、G3、a、b、c和d如本文所定义。还提供了将这些化合物用作脂质纳米粒子配方的组分以传递治疗剂、包含这些化合物的组合物以及其使用和制备方法。
• -Butyldiphenylsilylamines: A useful protecting group for primary amines
  作者：Larry E Overman、Mark E Okazaki、Pratibha Mishra

  DOI：10.1016/s0040-4039(00)84960-6

  日期：1986.1

  The utility of the -butyldiphenylsilyl group for protecting primary amines is explored. These derivatives are notably stable to chromatography, basic and hydrolytic reagents, as well as alkylating and acylating reagents. They are smoothly cleaved by mild acid and pyridine-HF.

  探索了-丁基二苯基甲硅烷基用于保护伯胺的用途。这些衍生物对色谱，碱性和水解试剂以及烷基化和酰化试剂特别稳定。它们被弱酸和吡啶-HF平稳裂解。
• TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY
  申请人：Bollu Venkataiah

  公开号：US20120040985A1

  公开（公告）日：2012-02-16

  The present invention comprises TGR5 agonists of structural formula I, wherein X, R 1 , R 2 , and R 5 are defined herein, as well as N-oxides of them and pharmaceutically acceptable salts thereof. The invention further comprises composition comprising the compounds, N-oxides, and/or pharmaceutically acceptable salts thereof. The invention also comprises use of the compounds and compositions for treating diseases in which TGR5 is a mediator or is implicated. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases in which TGR5 is a mediator or is implicated.

  本发明涉及结构式I的TGR5激动剂，其中X、R1、R2和R5如本文所定义，以及它们的N-氧化物和药学上可接受的盐。本发明还包括包含这些化合物、N-氧化物和/或药学上可接受的盐的组合物。本发明还包括使用这些化合物和组合物治疗TGR5是介质或被牵涉的疾病。本发明还包括使用这些化合物制造药物，特别是用于治疗TGR5是介质或被牵涉的疾病。